Proactive Investors - Run By Investors For Investors

Amryt Pharma's Dr Helen Phillips on 'remarkable' real-world Lojuxta study

Amryt Pharma PLC (LON:AMYT) currently has an exclusive licence to sell Lojuxta to adults in the EU and other territories including the Middle East, North Africa, Turkey and Israel.

Dr Helen Phillips, their head of medical affairs, talks through with Proactive's Andrew Scott their 'unexpected and exciting' findings from a real world study that's been done on the cholesterol-lowering drug.

 
View full AMYT profile View Profile

Amryt Pharma PLC Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use